FIG 1.
Survival outcomes in New Zealand White rabbits after challenge with B. anthracis spores at ∼200 times the LD50 and treatment with LVX (50 mg/kg daily for 3 days) plus a single i.v. dose of placebo or 40 mg/kg raxibacumab administered at 84 h postchallenge. (A) Primary endpoint analysis. The P value is based on a two-sided likelihood-ratio chi-square test. (B) Absolute improvement in day 28 survival by subgroup and 95% CI for the raxibacumab-LVX combination group compared with the LVX-alone group. X, point estimate; solid vertical line, 0% benefit; dashed vertical line, point estimate of the survival benefit in the overall (ITT) population. The 95% CIs were calculated by normal approximation. levo, levofloxacin; raxi, raxibacumab. (C) Survival time from the time of spore challenge. The P value was obtained from a log-rank test comparing the survival times between the raxibacumab-LVX combination group and the LVX-alone group.